Definition
Kaposi sarcoma (KS) is a vascular neoplasm caused by infection with human herpesvirus 8 (HHV-8, also known as Kaposi sarcoma-associated herpesvirus) which may involve the skin, mucous membranes or viscera. Epidemic KS is the form of the disease found among persons with HIV infection; it is the most common malignancy in persons with HIV worldwide.
Introduction
Kaposi sarcoma (KS) remains among the most common cancers seen in persons with human immunodeficiency virus (HIV) infection more than three decades after it was initially described as a key-presenting manifestation of the acquired immunodeficiency syndrome (AIDS) in 1981. While new cases of KS have decreased dramatically in the United States with the widespread availability of combination antiretroviral therapy (cART), the incidence remains threefold higher than prior to the HIV pandemic, and the cancer (Cancers Related to HIV) is the most common in the entire male population of several countries in sub-Saharan Africa....
This is a preview of subscription content, log in via an institution.
References
Achenbach CJ, Cole SR, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS. 2011;25(5):691–700.
Achenbach CJ, Harrington RD, et al. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis. 2012;54(3):424–33.
Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood. 2004;104(3):810–4.
Biggar RJ, Chaturvedi AK, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99(12):962–72.
Bihl F, Berger C, et al. Cellular immune responses and disease control in acute AIDS-associated Kaposi’s sarcoma. AIDS. 2009;23(14):1918–22.
Casper C, Redman M, et al. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr. 2004;35(3):233–8.
Chang Y, Cesarman E, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192):1865–9.
Dollard SC, Butler LM, et al. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the “Kaposi’s sarcoma belt”. Int J Cancer. 2010;127(10):2395–401.
Engels EA, Biggar RJ, et al. Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma. AIDS. 2003;17(12):1847–51.
Gantt S, Kakuru A, et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer. 2010;54(5):670–4.
Gondos A, Brenner H, et al. Cancer survival in Kampala, Uganda. Br J Cancer. 2005;92(9):1808–12.
Gregory SM, West JA, et al. Toll-like receptor signaling controls reactivation of KSHV from latency. Proc Natl Acad Sci U S A. 2009;106(28):11725–30.
Grulich AE, van Leeuwen MT, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.
Johnston C, Orem J, et al. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One. 2009;4(1):e4222.
Krown SE, Testa MA, et al. AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15(9):3085–92.
Martin JN, Ganem DE, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338(14):948–54.
Martin J, Laker M, et al. Kaposi’s sarcoma-associated immune reconstitution inflammatory syndrome (KS-IRIS) in Africa: initial findings from a prospective evaluation. Infect Agent Cancer. 2009;4 Suppl 2:17.
Nasti G, Martellotta F, et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer. 2003;98(11):2440–6.
Nguyen HQ, Magaret AS, et al. Persistent Kaposi sarcoma in the era of HAART: characterizing the predictors of clinical response. AIDS. 2008;22(8):937–45.
Pauk J, Huang ML, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med. 2000;343(19):1369–77.
Ribechini E, Fortini C, et al. Identification of CD8+ T cell epitopes within lytic antigens of human herpes virus 8. J Immunol. 2006;176(2):923–30.
Sabbah S, Jagne YJ, et al. T-cell immunity to Kaposi sarcoma‚ Äìassociated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells. Blood. 2012;119(9):2083–92.
Uldrick TS, Wang V, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51(3):350–8.
Vieira J, O’Hearn P, et al. Activation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol. 2001;75(3):1378–86.
Zong J, Ciufo DM, et al. Genotypic analysis at multiple loci across Kaposi’s sarcoma herpesvirus (KSHV) DNA molecules: clustering patterns, novel variants and chimerism. J Clin Virol. 2002;23(3):119–48.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this entry
Cite this entry
Casper, C. (2013). Current Understanding and Persistent Questions About the Pathogenesis and Presentation of Epidemic Kaposi Sarcoma. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_19-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9610-6_19-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-9610-6
eBook Packages: Springer Reference MedicineReference Module Medicine